Physician profile
William C Warnick
NPI 1710047790
$4,663.44
in general payments reported to CMS, 2019-2025
19 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2022: $394 · 2023: $1,237 · 2024: $1,421 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,113.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $578.26 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $411.64 | 2022-2025 | Repatha, Repatha |
| Bridgebio Pharma, INC. | $381.71 | 2025 | Attruby |
| Abbott Laboratories | $377.06 | 2022-2025 | Cardiomems |
| Pfizer INC. | $365.23 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.30 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $201.09 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $200.93 | 2023-2025 | Wainua, Farxiga |
| Impulse Dynamics (USA) INC. | $179.87 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $133.86 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $118.39 | 2023-2024 | |
| Esperion Therapeutics, INC. | $105.17 | 2023-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $73.68 | 2024 | Verquvo |
| Scpharmaceuticals INC. | $66.32 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.74 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $23.45 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $20.69 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.88 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Warnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.